STSalem M. Tos

Salem M. Tos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Salem M. Tos has a total of 299 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Single-session radiosurgery for Cushing disease after failed resection: a retrospective single-center cohort study

    by Bardia Hajikarimloo, Salem M Tos, Yuki Shinya, Onam Verma, Evan Mancini, Sean Morgan, Zhenye Li, Georgios Mantziaris, Gregory K Hong, Jason P Sheehan

    Context: Cushing disease (CD) from an adrenocorticotropic hormone-secreting pituitary adenoma causes substantial morbidity when hypercortisolism persists or recurs after transsphenoidal surgery (TSS). Objective: To define endocrine control, radiographic response, toxicity, and predictors after single-session Gamma Knife radiosurgery for residual or recurrent CD. Design: Retrospective single-center cohort study, 1990-2026; median endocrine follow-up 54 months. Setting: Single academic tertiary referral center. Patients: 186 adults with residual or recurrent CD after ≥1 TSS and ≥12 months of follow-up. Median age 40.8 years; 78.0% female. Intervention: Single-session frame-based SRS (median prescription dose 23.0 Gy; maximum dose 48.0 Gy). Main Outcome Measures: Prespecified primary outcome was durable biochemical control off medications (sustained 24-hour urinary free cortisol [UFC] normalization without cortisol-lowering therapy), modeled with competing-risks methodology. Results: UFC normalized in 152 patients (81.7%), including 134 (72.0%) off all medications. Cumulative incidence of durable off-medication control was 51% (95% CI: 44-58%) at 12 months and 64% (95% CI: 56-71%) at 120 months. New endocrinopathy reached 42% (95% CI: 32-52%) at 120 months; new visual deficit occurred in 3.2%. A TSS-to-SRS interval <6 months independently predicted higher durable control (P < .001), while higher baseline AM cortisol (P < .001), whole-sella treatment (P = .013), and female gender (P = .027) predicted lower durable control. Higher maximum dose was the sole independent predictor of new endocrinopathy (P = .009). Conclusion: Single-session SRS achieves durable medication-free control in approximately two-thirds of patients with residual or recurrent CD, with excellent tumor control and meaningful delayed endocrine toxicity warranting long-term surveillance.

  • Open Access

    Hypofractionated stereotactic radiotherapy/radiosurgery versus single-session stereotactic radiosurgery for patients with hemangioma of cavernous sinus: a systematic review, single-arm meta-analysis, and an indirect comparison

    by Muhammad Hussain Ahmadvand, Pouria Delbari, Mohammad Sina Mirjani, Bardia Hajikarimloo, Romina Hamidi Rad, Rasa Beheshti, Ibrahim Mohammadzadeh, Mohammad Amin Habibi, Milad Shafizadeh, Salem M. Tos, et al.

    Background Cavernous sinus hemangiomas (CSHs) are rare, benign vascular tumors with high morbidity due to their critical location and vascularity. While microsurgical resection was the historical standard, its risks of intraoperative bleeding and cranial nerve deficits have led to the adoption of stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (HSRT). This systematic review and meta-analysis evaluate outcomes of these modalities, focusing on tumor control, symptom relief, and safety. Methods Following PRISMA guidelines, a systematic search of PubMed, Embase, Web of Science, and Scopus (up to March 2024) identified studies reporting outcomes of SRS or HSRT in CSHs. Eligible studies were assessed for quality using the Joanna Briggs Institute checklist. All statistical analysis was performed using STATA v.17. Results Twenty studies with 682 patients were included. Tumor volume reduction was substantial, with a pooled estimate of 71% (95% CI: 57–84%) and a standardized mean difference of -2.07 (95% CI: -2.47 to -1.67). Symptom recovery rates were highest with HSRT (64%, 95% CI: 9–119%) compared to SRS (44%, 95% CI: 21–67%). Adverse radiation effects were minimal, with an overall rate of 5% (95% CI: 2–7%). Cranial nerve improvement was observed but varied by nerve and treatment type. Conclusion SRS and HSRT are effective and safe for CSHs, with HSRT showing particular benefits for larger tumors due to fractionation. Future studies should optimize protocols and refine patient selection to maximize therapeutic outcomes. Radiation-based therapies now represent a cornerstone in CSH management.

  • Dose De-escalation in Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients on Concurrent Immunotherapy or Targeted Therapy: A Multicenter Experience

    by Salem M. Tos, Bardia Hajikarimloo, Georgios Mantziaris, Nicholas D. Cassimatis, Stylianos Pikis, Mariam Ishaque, Carson Brantley, L. Dade Lunsford, Ajay Niranjan, Zhishuo Wei, et al.

    BACKGROUND AND OBJECTIVES: The American Society for Radiation Oncology guidelines for stereotactic radiosurgery dose suggestions for brain metastases provide excellent local control but at the expense of higher adverse radiation effects (ARE). This study provides evidence that lower single-fraction prescription doses for patients with melanoma metastases who are concurrently receiving immunotherapy or targeted therapy are equally effective and safe. METHODS: This retrospective, multicenter study included 335 patients with melanoma brain metastases who underwent stereotactic radiosurgery between 2009 and 2024. After covariate balancing, 137 patients with 590 metastases were included in the high dose (HD) group and 59 patients with 590 metastases in the reduced dose (RD) group. The RD limits were set at P = .5) and imaging follow-up (6 vs 6 months, P = .13) were comparable. Cumulative incidence of progressing metastases was significantly higher in the HD group compared with the RD group ( P < .001) overall, but lower prescription doses resulted in higher progression rates for metastases >2 cm ( P = .023). Higher prescription volumes and HD-group prescription doses were linked with local progression in multivariable analysis. Radiographic AREs were significantly more common in the HD group compared with the RD group overall ( P < .001) but similar for metastases >2 cm ( P = .7). Higher prescription volumes, HD-group prescription doses, and concurrent BRAF or other tyrosine kinase inhibitors were linked with an increased risk of radiographic ARE, whereas concurrent immunotherapy was associated with lower rates of radiographic ARE. CONCLUSION: This study provides evidence that treatment with prescription doses under the currently the American Society for Radiation Oncology-suggested doses for brain melanoma metastases <2 cm is safe, having at least equal local control rate and lower radiographic AREs. Reducing prescription dose for lesions between 2 and 3 cm does not seem to convey reduced ARE rates and could potentially increase local failure.


  • Open Access

    Safety and effectiveness of stereotactic radiosurgery for larger hemangioblastomas (>2cc): A multi-center retrospective study

    by Pavel S. Pichardo-Rojas, Salem M Tos, Georgios Mantziaris, Ahmed Shaaban, Ahmed M. Nabeel, Wael A. Reda, Sameh R. Tawadros, Khaled AbdelKarim, Amr M. N. El-Shehaby, Reem M Emad, et al.

    Introduction: Hemangioblastomas (HGB) are the most common primary intra-axial tumors in the posterior fossa in adults, with an overall occurrence of 7–10%. They occur sporadically or as part of von Hippel-Lindau (VHL) disease. The role of stereotactic radiosurgery (SRS) as a minimally invasive treatment in larger HGB (>2cc) has not been thoroughly investigated. Methods: This multi-center study retrospectively analyzed data from 91 patients with large HGB (>2cc) treated between 1993 and 2023. Patients were stratified into VHL-associated and sporadic groups, with assessments including radiosurgical parameters, tumor response, overall survival (OS), and progression-free survival (PFS). Results: Patients with VHL-associated HGB were younger at diagnosis (median: 33 years vs. 52 years, p < 0.001) and presented more frequently with multiple tumors (68.8% vs. 23.2%, p < 0.001). Cerebellar lesions were the most common location (70%), followed by brainstem lesions (21%). The median target tumor volume was smaller in VHL cases (3.49 cc vs. 6.5 cc, p = 0.038). Tumor control was achieved in 70% of cases across groups, with no significant differences in outcomes between VHL and sporadic cases. OS (170 months for VHL and 199 months for sporadic cases) and PFS (108 months for both groups) were comparable. Radiation necrosis was observed in 8.8% of patients. Conclusions: SRS may provide favorable tumor control with low morbidity in both VHL-associated and sporadic cases of larger HGB (>2 cc).Future studies should compare SRS with resection for larger HGB and explore molecular predictors of favorable response to SRS.

  • Repeat stereotactic radiosurgery for pituitary adenomas: a systematic review and meta-analysis

    by Bardia Hajikarimloo, Ibrahim Mohammadzadeh, Salem M. Tos, Ali Mortezaei, Mohammad Amin Habibi

  • Stereotactic Radiosurgery Dose Reduction for Patients With Brain Metastases From Non–Small Cell Lung Primary on Immunotherapy or Targeted Therapy

    by Jared H. Chung, Salem M. Tos, Georgios Mantziaris, Yuki Shinya, Bardia Hajikarimloo, Jack Guiry, Abhinav Kareddy, Tanvika Vegiraju, Edward Llinas, David Penberthy, et al.

    BACKGROUND AND OBJECTIVES: Lung cancer is the most common primary neoplasm that metastasizes to the brain. Although stereotactic radiosurgery (SRS) using American Society for Radiation Oncology guideline–suggested doses improves local control, it may increase adverse radiation events (AREs). This study evaluates whether reduced SRS doses can achieve comparable local control while minimizing toxicity in patients with brain metastases from non–small cell lung cancer (NSCLC) primary receiving concurrent systemic therapy. METHODS: We conducted a retrospective study of 264 patients with 1390 metastases from lung primary treated with SRS between December 2015 and January 2025. Of these, 82 patients with 433 metastases had NSCLC and received concurrent systemic therapy, defined as immunotherapy or targeted therapy within 30 days of SRS. Propensity score matching identified 38 patients with 93 metastases in the higher-dose (HD) group (20-24 Gy for P = .020). Local control was noninferior in the RD group (94.6%) compared with the HD group (90.3%, P = .400). Cumulative progression at 1, 3, and 5 years remained comparable between the RD (13%, 15%, and 15%, respectively) and HD (7.2%, 10%, and 10%, respectively) groups ( P = .500). CONCLUSION: In the contemporary era, RD SRS delivered concurrently with immunotherapy or targeted therapy may lower AREs without compromising local control to treat NSCLC brain metastases.


  • Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance

    by Salem M Tos, Ahmed Shaaban, Dawoud Hamdan, Georgios Mantziaris, Bardia Hajikarimloo, Mariam Ishaque, Yuki Shinya, Vanshika Lohia, Zhishuo Wei, Orbay Askeroglu, et al.

    Background: Intracranial solitary fibrous tumors (SFTs) are rare, aggressive neoplasms with high local recurrence. This study evaluates the efficacy and prognostic factors of single-fraction stereotactic radiosurgery (SRS). Methods: This multicenter retrospective study included 107 patients (253 SFTs) treated with single-fraction SRS at 18 centers (1989-2024). We analyzed local control (LC), intracranial tumor control (ITC), overall tumor control (OTC), progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS). Cox regression identified prognostic factors. Results: Median follow-up was 33 months. LC was 68.4% (5-year: 56.8% and 10-year: 38.8%). ITC 54.2% (5-year: 48.5%) and OTC 50.5% (5-year: 44.0%). PFS was 56.3% and 30.2% at 5 and 10 years, respectively. DSS remained high at 89.7% (5-year) and 79.7% (10-year), while OS was 79.3% (5-year) and 55.2% (10-year). Independent predictors of LC included recurrent versus metastatic SFTs (HR: 1.96, P = 0.028), margin dose ≤16 Gy (HR: 2.35, P = 0.006), larger tumor volume (HR: 1.05, P < 0.001), and longer diagnosis-to-SRS duration (HR: 1.02, P < 0.001). Older age (HR: 1.03, P = 0.014) and longer resection-to-SRS duration (HR: 1.02, P = 0.018) predicted worse ITC. Age significantly affected OS (HR: 1.06, P < 0.001) and PFS (HR: 1.03, P = 0.037). Longer diagnosis-to-SRS (HR: 1.03, P = 0.002) and resection-to-SRS durations (HR: 1.02, P = 0.030) predicted worse PFS. KPS score >70 predicted better outcomes across ITC, OTC, DSS, and OS. Radiation-related adverse effects occurred in 2.8%. Conclusion: Single-fraction stereotactic radiosurgery offers reasonable tumor control and favorable long-term survival in the adjuvant and salvage setting for patients with residual, recurrent, or metastatic intracranial SFTs. Key prognostic factors included tumor volume, recurrence status, and timing of SRS.

  • Microvascular decompression in glossopharyngeal neuralgia: a systematic review and meta-analysis

    by Bardia Hajikarimloo, Ibrahim Mohammadzadeh, Salem M. Tos, Ali Mortezaei, Mohammad Amin Habibi

    Objective Glossopharyngeal neuralgia (GPN) is a rare craniofacial pain disorder causing paroxysmal throat and ear pain. For medically refractory cases, microvascular decompression (MVD) targets the underlying neurovascular compression and offers a potentially curative treatment. This systematic review and meta-analysis aimed to evaluate the efficacy, safety, and durability of MVD for GPN and identify predictors of outcome. Methods A comprehensive search of PubMed, Embase, Scopus, and Web of Science was conducted up to August 24, 2025, following PRISMA guidelines. Eligible studies included patients with clinically or radiologically confirmed GPN treated with MVD. Pooled estimates were calculated using random- or fixed-effects models, and heterogeneity, publication bias, and meta-regression analyses were performed. Results Twenty-five studies encompassing 1,009 patients were analyzed. The pooled rate of initial complete pain relief was 94.2% (95% CI: 90.2–97.3%), and long-term complete relief was 92.1% (95% CI: 86.9–96.2%). Pain recurrence occurred in 2.3% (95% CI: 0.5–4.8%), and permanent complications in 1.7% (95% CI: 0.2–4.2%). Meta-regression identified longer disease duration and prior MVD as negative predictors, while arterial compression and older age favored better outcomes. Conclusion MVD provides excellent and durable pain relief with minimal morbidity, confirming its role as the gold-standard treatment for classical GPN. Prospective, standardized studies are warranted to refine patient selection and optimize outcomes.


  • Outcomes of Repeat Stereotactic Radiosurgery for Recurrent or Progressive Sporadic Vestibular Schwannoma: A Multicenter International Study

    by Salem M. Tos, Mariam Ishaque, Georgios Mantziaris, Bardia Hajikarimaloo, Keiss Douri, David Mathieu, Ahmed M. Nabeel, Wael A. Reda, Sameh R. Tawadros, Khaled Abdelkarim, et al.

    BACKGROUND AND OBJECTIVES: Repeat stereotactic radiosurgery (SRS) is a noninvasive option for recurrent vestibular schwannoma (VS). This study evaluates outcomes in patients with long-term follow-up. METHODS: This retrospective multicenter study analyzed 81 patients with recurrent unilateral sporadic VS after initial SRS, with ≥12 months of follow-up. Outcomes included tumor control, hearing preservation, cranial nerve function, and adverse radiation effects (ARE). Kaplan-Meier and Cox regression identified factors affecting outcomes. RESULTS: The median age at the second SRS was 60 years, with a median interval of 58 months between procedures. The median margin doses were 12.0 Gy (single-fraction), 17.25 Gy (3-fraction), and 25 Gy (5-fraction). Tumor control was achieved in 69 patients (85.2%), with 5- and 10-year local control rates of 82% and 76.5%, respectively. Significant predictors of local failure included tumor volume >2.2 cm 3 (area under the curve = 0.757, P = .018), prescription biological effective dose (BED) ≤70.3 Gy (hazard ratio [HR]: 0.89, P = .003), and interval between treatments >27.5 months (HR: 1.02, P = .015). In single-fraction SRS, higher prescription dose reduced failure risk (HR: 0.31, P = .002) with a margin dose ≥12 Gy being critical for improved tumor control ( P < .001). Serviceable hearing was retained in 12 of 18 cases (66.7%), and facial nerve function was preserved in 72 of 80 cases (90%). ARE occurred in 11 patients (13.6%), most commonly perilesional edema (63.7%). ARE correlated with higher brainstem maximum BED in the entire cohort (HR: 1.02, P = .016) and in single-fraction SRS (HR: 1.02, P = .006). Pseudoprogression (9.8%) was linked to younger age (HR: 0.88, P = .023) and shorter time between SRS (HR: 0.87, P = .012). CONCLUSION: Repeat SRS is an effective option for recurrent sporadic VS, offering high tumor control and functional preservation. Outcomes depend on age, interval between treatments, tumor volume, and BED. With careful planning, adverse effects are rare and typically transient.


  • The clinical outcomes of combined stereotactic radiosurgery with PD-1/PD-L1 inhibitors in patients with metastatic brain tumors: a systematic review and meta-analysis on the safety and efficacy

    by Muhammad Hussain Ahmadvand, Mohammad Amin Habibi, Mohammad Sina Mirjani, Amirmohammad Bahri, Fateme Aghaei, Amirmahdi Foroughi, Yalda Ghazizadeh, Mohammad Shahir Eftekhar, Hossein Gandomkar, Pouria Delbari, et al.

    Brain metastases (BM) pose a significant challenge due to limited treatment options and poor prognosis. Combining PD-1/PD-L1 inhibitors with stereotactic radiosurgery (SRS) may enhance tumor control through synergistic effects. This study assessed the efficacy and safety of this combined approach for BM. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, Web of Science, and Scopus up to 27 June 2024. Studies involving PD-1/PD-L1 inhibitors and SRS for BM were included. Outcomes included local control (LC), progression-free survival (PFS), overall survival (OS), radiological response, and adverse events. Data were analyzed using STATA V.17 with a random-effects model. Sixteen studies with 1529 patients were included. Pooled 6- and 12-month LC rates were 85% (95% CI 75–95%) and 84% (95% CI 75–93%), respectively. One- and three-year PFS rates were both 51% (95% CI 39–64% and 41–62%), while one- and two-year OS rates were 67% (95% CI 57–78%) and 30% (95% CI 16–45%). Overall response rate was 61% (95% CI 44–78%), with a complete response rate of 39% (95% CI 25–53%). Adverse radiation effects occurred in 31% (95% CI 3–58%), with radiation necrosis in 12% (95% CI 2–23%). Subgroup analyses showed no significant impact of drug type, primary tumor site, prior treatment, or SRS fractionation on outcomes. Combining PD-1/PD-L1 inhibitors with SRS for BM yields robust local control and improved one-year survival compared to historical data, with manageable toxicities. However, variability in outcomes and lack of comparator groups highlight the need for standardized protocols and prospective trials to optimize treatment strategies and identify predictive biomarkers.